Papers › pregnancy › 9004487

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

The Lancet. Oncology · 01-8-2015 · 9004487 on PMC →

1,555 citations FWCI 103.14 Cancer Immunotherapy and Biomarkers Read PDF → Trend

Citation data as of 2026-04-12 (OpenAlex).

Extracted findings

This paper hasn't been extracted into the knowledge graph yet. We're working through the corpus — 9004487 is in the queue.

In the meantime: Browse pregnancy papers → · Ask about this topic → · Explore the graph →